Orcef30 ml

Orcef 30 ml is an orally administered, third-generation cephalosporin antibiotic with potent bactericidal activity against a broad spectrum of Gram-positive and Gram-negative microorganisms. It is indicated for the treatment of the following acute bacterial infections caused by susceptible strains:

1. Upper Respiratory Tract Infections (URTI)

Cefixime is indicated for bacterial URTIs including:

• Otitis media (middle ear infection)
• Pharyngitis and tonsillitis caused by Streptococcus pyogenes
• Other upper respiratory infections where the causative organism is known or suspected to be resistant to commonly used antibiotics (e.g., amoxicillin), or where treatment failure poses significant clinical risk

2. Lower Respiratory Tract Infections (LRTI)

• Acute bronchitis and acute exacerbations of chronic bronchitis caused by susceptible organisms such as Haemophilus influenzae and Moraxella catarrhalis

3. Urinary Tract Infections (UTI)

Cefixime is effective for uncomplicated and complicated UTIs, including:

• Cystitis (bladder infection)
• Cystourethritis (combined bladder and urethral infection)
• Pyelonephritis (kidney infection)

Beta-Lactamase Stability

Orcef 30 ml demonstrates high stability against beta-lactamase enzymes, making it an effective treatment option for infections caused by organisms resistant to penicillins and earlier-generation cephalosporins. This property is particularly significant for pathogens such as H. influenzae and M. catarrhalis that commonly produce beta-lactamase.

Note: Cefixime should only be used when the infection is confirmed or strongly suspected to be caused by susceptible bacteria. Prescribing in the absence of proven or strongly suspected bacterial infection increases the risk of antibiotic resistance.

Third generation Cephalosporins

Orcef 30 ml is a third-generation semisynthetic cephalosporin antibiotic designed for oral administration. It belongs to the β-lactam class of antibiotics and is widely used for treating a broad range of bacterial infections caused by susceptible organisms.

Mechanism of Action

Cefixime exhibits a bactericidal effect, meaning it actively kills bacteria rather than merely inhibiting their growth. It works by:

• Inhibiting bacterial cell wall synthesis
• Binding to penicillin-binding proteins (PBPs)
• Disrupting the formation of peptidoglycan, an essential structural component of the bacterial cell wall

As a result, the bacterial cell wall becomes weak and unstable, leading to cell lysis and death.

Antibacterial Spectrum

Cefixime demonstrates a broad-spectrum antibacterial activity, effective against many:

• Gram-positive bacteria
• Gram-negative bacteria

It achieves this activity at therapeutically attainable plasma concentrations, making it clinically effective in routine dosing.

Beta-Lactamase Stability

One of the key pharmacological advantages of Cefixime is its high stability against beta-lactamase enzymes. These enzymes are produced by many resistant bacteria to inactivate β-lactam antibiotics.

Because Cefixime is resistant to beta-lactamase degradation:

• It remains effective against many organisms resistant to penicillins
• Some cephalosporin-resistant strains may still show susceptibility
• It expands treatment options in resistant bacterial infections

Absorption and Bioavailability

After oral administration, Cefixime shows moderate absorption:

• Bioavailability: approximately 40% to 50%
• Absorption is not significantly affected by food intake, meaning it can be taken with or without meals

This predictable absorption profile helps maintain consistent therapeutic drug levels in the bloodstream.

Summary

Orcef 30 ml is an orally active, broad-spectrum, beta-lactamase-stable cephalosporin antibiotic that works by inhibiting bacterial cell wall synthesis. With moderate but reliable absorption and strong activity against resistant organisms, it is widely used in clinical practice for various bacterial infections.

Orcef 30 ml may interact with certain medications, particularly those affecting blood coagulation. Although it has a relatively low interaction profile compared to many antibiotics, careful monitoring is still recommended in specific clinical situations.

Interaction with Anticoagulants

In common with other cephalosporin antibiotics, Cefixime has been associated with increased prothrombin time (PT) in some patients. This effect may enhance the risk of bleeding, especially in individuals taking blood-thinning agents.

Clinical Considerations:

• Patients receiving anticoagulant therapy should be closely monitored
• Regular assessment of prothrombin time / INR may be required
• Dose adjustment of anticoagulants may be necessary based on clinical response

Key Safety Note

Although the interaction is not common, the potential for altered coagulation parameters warrants caution, particularly in patients with:

• Long-term anticoagulant use
• Bleeding disorders
• Liver dysfunction or other conditions affecting clotting factors

Summary

Orcef 30 ml is generally well tolerated with a low risk of drug interactions. However, it may increase prothrombin time, so special caution is advised when used concurrently with anticoagulant medications to prevent potential bleeding complications.

Orcef 30 ml is generally well tolerated in most patients. In clinical studies, the majority of adverse reactions were mild, transient, and self-limiting, often resolving after discontinuation of therapy.

Gastrointestinal Side Effects

Gastrointestinal symptoms are the most commonly reported adverse effects, including:

• Diarrhea (most frequent; more common with higher doses)
• Stool changes
• Nausea
• Abdominal pain
• Dyspepsia (indigestion)
• Vomiting
• Flatulence (gas)

In rare cases, pseudomembranous colitis has been reported, which is a serious intestinal condition associated with antibiotic use.

Central Nervous System Effects

Some patients may experience mild neurological symptoms such as:

• Headache
• Dizziness

These effects are typically temporary and resolve without specific treatment.

Hypersensitivity Reactions

Allergic reactions may occur in sensitive individuals, including:

• Skin rash
• Pruritus (itching)
• Urticaria (hives)
• Drug fever
• Arthralgia (joint pain)

These reactions generally resolve after discontinuation of the medication.

Hematological and Laboratory Changes

Infrequent but reversible changes in blood and laboratory parameters may include:

• Thrombocytopenia (low platelet count)
• Leukopenia (reduced white blood cells)
• Eosinophilia (increased eosinophils)
• Mild and transient changes in liver and renal function tests

Other Possible Effects

Additional uncommon effects reported include:

• Genital pruritus (itching)
• Vaginitis

Summary

Orcef 30 ml is generally safe and well tolerated, with side effects that are mostly mild and reversible. The most common reactions involve the gastrointestinal system, while allergic, neurological, hematological, and laboratory changes occur less frequently and usually resolve after stopping therapy.

Orcef 30 ml should be used during pregnancy and breastfeeding only when clearly necessary, as clinical evidence in these populations is limited.

Use in Pregnancy

There are no adequate and well-controlled studies in pregnant women to fully establish safety.

Key considerations:

• Animal reproduction studies do not always reliably predict human outcomes
• Therefore, Cefixime should be used in pregnancy only if clearly needed
• The potential benefits to the mother must outweigh any possible risks to the fetus
• Use should be based on careful clinical judgment by a healthcare professional

Use During Lactation (Breastfeeding)

Information regarding excretion into human breast milk is not clearly established.

Key points:

• It is not confirmed whether Cefixime is excreted in human milk
• Caution is advised when administering to nursing mothers
• The decision to continue breastfeeding or therapy should consider:
  • Maternal clinical need
  • Potential risk to the infant
  • Possible alternative treatments

Clinical Summary

Orcef 30 ml should be prescribed during pregnancy and lactation only after careful risk–benefit evaluation. Due to limited human data, cautious use is recommended to ensure maternal benefit while minimizing potential risk to the fetus or nursing infant.

Orcef 30 ml should be used with caution in patients with a history of drug hypersensitivity, renal impairment, or antibiotic-associated gastrointestinal disorders. Careful clinical monitoring is important to ensure safe and effective therapy.

Hypersensitivity Reactions

Cefixime should be administered cautiously in patients with a history of:

• Hypersensitivity to other drugs
• Allergic reactions to antibiotics

Special caution is required because:

• There is partial cross-allergenicity between penicillins and cephalosporins
• Patients sensitive to penicillin may also react to cephalosporins
• Severe allergic reactions, including anaphylaxis, have been reported with both drug classes

If an allergic reaction occurs:

• Cefixime should be immediately discontinued
• Appropriate medical treatment should be initiated as required

Renal Impairment

Caution is advised in patients with markedly impaired renal function:

• Dose adjustment may be necessary
• Renal function should be monitored during prolonged therapy
• Accumulation of the drug may occur in severe kidney impairment

Antibiotic-Associated Diarrhea & Clostridium difficile Risk

Like other broad-spectrum antibiotics, Cefixime may alter normal intestinal flora, leading to:

• Overgrowth of Clostridium species
• Risk of antibiotic-associated diarrhea
• Possible development of Clostridium difficile toxin-related colitis

Patients should be monitored for persistent or severe diarrhea during or after treatment.

Use in Pregnancy & Lactation

Due to lack of adequate controlled studies:

• Cefixime should be used in pregnancy only if clearly essential
• Caution is advised in nursing mothers
• Use only when the expected benefits outweigh potential risks

Summary

Orcef 30 ml should be used with caution in patients with allergy history, renal dysfunction, and during pregnancy or lactation. Close monitoring is recommended to prevent hypersensitivity reactions, renal complications, and antibiotic-associated intestinal disturbances, ensuring safe therapeutic outcomes.

Orcef 30 ml has a relatively wide safety margin, and serious toxicity from overdose is uncommon. Clinical data suggest that even high single doses do not typically produce effects significantly different from standard therapeutic use.

Clinical Manifestations

In limited studies involving healthy adult volunteers, single doses up to 2 g of Cefixime did not show any new or unexpected adverse effects compared to standard dosing. This indicates that overdose is generally associated with an extension of known side effects rather than severe toxic reactions.

Possible symptoms in overdose situations may include:

• Exaggeration of common side effects (e.g., gastrointestinal discomfort, diarrhea)
• Generalized adverse reactions similar to therapeutic dosing profiles

Management of Overdose

There is no specific antidote for Cefixime overdose.

Recommended management includes:

• Gastric lavage may be considered if ingestion is recent and clinically appropriate
• Supportive and symptomatic treatment is the mainstay of care
• Monitoring of vital signs and clinical status as needed

Role of Dialysis

Elimination of Cefixime via dialysis is limited:

• The drug is not significantly removed by hemodialysis
• It is also not effectively cleared by peritoneal dialysis

Therefore, dialysis is not an effective treatment method for overdose management.

Summary

Orcef 30 ml overdose is generally not associated with severe toxicity. Management is mainly supportive, as there is no specific antidote and dialysis does not significantly enhance drug elimination. Most cases involve mild, self-limiting symptoms consistent with the drug’s known adverse effect profile.

Keep below 30ºC temperature, protected from light & moisture. Keep out of the reach of children.

Third generation Cephalosporins

Cefixime is a third generation semisynthetic cephalosporin antibiotic for oral administration. It is bactericidal against a broad spectrum of gram positive and gram negative bacteria at easily achievable plasma concentrations. It kills bacteria by interfering in the synthesis of bacterial cell wall. It is highly stable in the presence of Beta-lactamase enzyme. As a result, many organisms resistant to penicillins and some cephalsporins due to the presence of beta-lactamases, may be susceptible to Cefixime. Absorption of it is about 40% to 50% whether administered with or without food.

There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. It is not known that Cefixime is excreted in human milk. So, caution should be exercised when Cefixime is administered to a nursing woman.